Dr. McGregor on Whether Patients Need Frontline Combinations in RCC

Video

Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses whether patients with renal cell carcinoma (RCC) need frontline combination therapy.

Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses whether patients with renal cell carcinoma (RCC) need frontline combination therapy.

Frontline combination therapies have taken hold of the RCC landscape, but physicians have yet to determine whether everyone should receive a frontline combination therapy, says McGregor. In the CheckMate-214 trial, the combination of ipilimumab (Yervoy) and nivolumab (Opdivo) was compared with sunitinib (Sutent) in the frontline setting and showed an improvement in overall survival. However, patients with good-risk disease demonstrated a higher rate of progression-free survival with sunitinib than with the combination.

Additionally, patients in the trial were accrued prior to the FDA’s approval of the combination in the United States. Less than 30% of patients who received sunitinib crossed over to receive immunotherapy in the trial. Researchers did not allow crossover until the data were reported, which was in 2016. Therefore, it is unknown if patients who receive frontline sunitinib and second-line immunotherapy experience the same magnitude of benefit, explains McGregor.

Recent Videos
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
Arun Upadhyay, PhD, the chief scientific officer and head of research, development, and Medical at Ocugen
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
Barry J. Byrne, MD, PhD, the chief medical advisor of Muscular Dystrophy Association (MDA) and a physician-scientist at the University of Florida
John Brandsema, MD, a pediatric neurologist in the Division of Neurology at Children’s Hospital of Philadelphia
© 2024 MJH Life Sciences

All rights reserved.